Compare CTKB & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTKB | NNNN |
|---|---|---|
| Founded | 1990 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.1M | 434.5M |
| IPO Year | 2021 | 2023 |
| Metric | CTKB | NNNN |
|---|---|---|
| Price | $4.74 | $8.49 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.63 | N/A |
| AVG Volume (30 Days) | ★ 791.4K | 32.9K |
| Earning Date | 05-07-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $193,015,000.00 | N/A |
| Revenue This Year | $5.42 | N/A |
| Revenue Next Year | $7.03 | N/A |
| P/E Ratio | ★ N/A | $446.57 |
| Revenue Growth | ★ 17.67 | N/A |
| 52 Week Low | $3.28 | $8.30 |
| 52 Week High | $6.18 | $54.50 |
| Indicator | CTKB | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 58.18 | 31.56 |
| Support Level | $4.15 | N/A |
| Resistance Level | $5.24 | $12.62 |
| Average True Range (ATR) | 0.22 | 2.18 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 73.03 | 12.20 |
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).